Phase 3 clinical trial for MK-3655
Latest Information Update: 14 Jan 2019
At a glance
- Drugs MK 3655 (Primary)
- Indications Non-alcoholic fatty liver disease; Obesity
- Focus Therapeutic Use
Most Recent Events
- 14 Jan 2019 New trial record
Latest Information Update: 14 Jan 2019